Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

328 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure.
Torre-Amione G, Young JB, Colucci WS, Lewis BS, Pratt C, Cotter G, Stangl K, Elkayam U, Teerlink JR, Frey A, Rainisio M, Kobrin I. Torre-Amione G, et al. Among authors: cotter g. J Am Coll Cardiol. 2003 Jul 2;42(1):140-7. doi: 10.1016/s0735-1097(03)00556-4. J Am Coll Cardiol. 2003. PMID: 12849674 Free article. Clinical Trial.
High-dose intravenous isosorbide-dinitrate is safer and better than Bi-PAP ventilation combined with conventional treatment for severe pulmonary edema.
Sharon A, Shpirer I, Kaluski E, Moshkovitz Y, Milovanov O, Polak R, Blatt A, Simovitz A, Shaham O, Faigenberg Z, Metzger M, Stav D, Yogev R, Golik A, Krakover R, Vered Z, Cotter G. Sharon A, et al. Among authors: cotter g. J Am Coll Cardiol. 2000 Sep;36(3):832-7. doi: 10.1016/s0735-1097(00)00785-3. J Am Coll Cardiol. 2000. PMID: 10987607 Free article. Clinical Trial.
Tezosentan (an intravenous endothelin receptor A/B antagonist) reduces peripheral resistance and increases cardiac power therefore preventing a steep decrease in blood pressure in patients with congestive heart failure.
Cotter G, Kiowski W, Kaluski E, Kobrin I, Milovanov O, Marmor A, Jafari J, Reisin L, Krakover R, Vered Z, Caspi A. Cotter G, et al. Eur J Heart Fail. 2001 Aug;3(4):457-61. doi: 10.1016/s1388-9842(01)00168-4. Eur J Heart Fail. 2001. PMID: 11511432 Free article. Clinical Trial.
RITZ-5: randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, double-blind, placebo-controlled study.
Kaluski E, Kobrin I, Zimlichman R, Marmor A, Krakov O, Milo O, Frey A, Kaplan S, Krakover R, Caspi A, Vered Z, Cotter G. Kaluski E, et al. Among authors: cotter g. J Am Coll Cardiol. 2003 Jan 15;41(2):204-10. doi: 10.1016/s0735-1097(02)02708-0. J Am Coll Cardiol. 2003. PMID: 12535809 Free article. Clinical Trial.
Prior peripheral arterial disease and cerebrovascular disease are independent predictors of adverse outcome in patients with acute coronary syndromes: are we doing enough? Results from the Orbofiban in Patients with Unstable Coronary Syndromes-Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study.
Cotter G, Cannon CP, McCabe CH, Michowitz Y, Kaluski E, Charlesworth A, Milo O, Bentley J, Blatt A, Krakover R, Zimlichman R, Reisin L, Marmor A, Lewis B, Vered Z, Caspi A, Braunwald E; OPUS-TIMI 16 Investigators. Cotter G, et al. Am Heart J. 2003 Apr;145(4):622-7. doi: 10.1067/mhj.2003.6. Am Heart J. 2003. PMID: 12679757 Clinical Trial.
The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A/B receptor antagonist) in patients with acute heart failure.
Cotter G, Kaluski E, Stangl K, Pacher R, Richter C, Milo-Cotter O, Perchenet L, Kobrin I, Kaplan S, Rainisio M, Frey A, Neuhart E, Vered Z, Dingemanse J, Torre-Amione G. Cotter G, et al. Eur J Heart Fail. 2004 Aug;6(5):601-9. doi: 10.1016/j.ejheart.2004.05.004. Eur J Heart Fail. 2004. PMID: 15302008 Free article. Clinical Trial.
Echocardiographic ejection fraction in patients with acute heart failure: correlations with hemodynamic, clinical, and neurohormonal measures and short-term outcome.
Uriel N, Torre-Amione G, Milo O, Kaluski E, Perchenet L, Blatt A, Kobrin I, Turnovski A, Kaplan S, Rainisio M, Frey A, Vered Z, Cotter G. Uriel N, et al. Among authors: cotter g. Eur J Heart Fail. 2005 Aug;7(5):815-9. doi: 10.1016/j.ejheart.2004.10.013. Eur J Heart Fail. 2005. PMID: 16087136 Free article.
Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension--a multi-center randomized study.
Kaluski E, Cotter G, Leitman M, Milo-Cotter O, Krakover R, Kobrin I, Moriconi T, Rainisio M, Caspi A, Reizin L, Zimlichman R, Vered Z. Kaluski E, et al. Among authors: cotter g. Cardiology. 2008;109(4):273-80. doi: 10.1159/000107791. Epub 2007 Sep 17. Cardiology. 2008. PMID: 17873492 Clinical Trial.
Hemodynamic monitoring in acute heart failure.
Cotter G, Cotter OM, Kaluski E. Cotter G, et al. Among authors: cotter om. Crit Care Med. 2008 Jan;36(1 Suppl):S40-3. doi: 10.1097/01.CCM.0000296280.71595.64. Crit Care Med. 2008. PMID: 18158476 Review.
328 results